|Bid||10,702.00 x 0|
|Ask||10,704.00 x 0|
|Day's range||10,512.00 - 10,740.00|
|52-week range||8,029.00 - 11,289.62|
|Beta (5Y monthly)||0.10|
|PE ratio (TTM)||133.40|
|Earnings date||28 Apr 2022 - 02 May 2022|
|Forward dividend & yield||2.22 (1.93%)|
|Ex-dividend date||11 Aug 2022|
|1y target est||114.44|
WILMINGTON, Del., August 12, 2022--AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by a Food and Drug Administration (FDA)-approved test, and who have received a prior systemic therapy.
Large corporations are jumping on the "green" bandwagon left and right, which in turn is pushing firms that lease and manage car fleets to convert to electric vehicles (EVs) faster than they had ever thought possible. In late 2020, fleet management company ALD set a to have 30% of its new cars electrified by 2025 - a goal that seemed like a stretch because as recently as 2019 only one in 200 of ALD's new vehicles was an EV or a hybrid. But corporate clients chasing environmental, social and governance (ESG) goals pushed the leasing giant, a unit of Societe Generale, past that target in 2021.
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.